SCHEMBL19862020

SCHEMBL19862020

CC1=NOC(C)c2cc(-c3ccc(F)cc3)ccc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 1/20 0.35
HTR2C P28335 1/20 0.34
PDE3B Q13370 4/20 0.33
PDE3A Q14432 4/20 0.33
PGR P06401 1/20 0.32
TSHR P16473 2/20 0.32
GAA P10253 1/20 0.32
MAP4K4 O95819 1/20 0.32
CYP3A4 P08684 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31
MEN1 O00255 3/20 0.31
KMT2A Q03164 3/20 0.31
NPC1 O15118 1/20 0.31
ALOX15 P16050 1/20 0.31
RAB9A P51151 1/20 0.31
APAF1 O14727 1/20 0.31
POLB P06746 1/20 0.31
GRK2 P25098 1/20 0.31
APOBEC3G Q9HC16 1/20 0.31
GCGR P47871 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21122855 0.84 UGCG (0.35) UGCGHTR2CPDE3BPDE3APGR
SCHEMBL18069876 0.79 UGCG (0.43) UGCGPDE3BPDE3AMAP4K4CYP3A4
SCHEMBL19862027 0.68 CYP3A4 (0.40) UGCGPDE3BPDE3APGRCYP3A4
SCHEMBL12011033 0.59 ACHE (0.52) PDE3BPDE3ACYP3A4TNKS2MEN1
SCHEMBL14206975 0.59 ACHE (0.52) PDE3BPDE3ACYP3A4TNKS2MEN1
SCHEMBL19862021 0.58 CYP3A4 (0.45) UGCGHTR2CPGRCYP3A4MEN1
SCHEMBL10304735 0.58 TNKS2 (0.47) PGRTSHRCYP3A4TNKS2MAPK14
SCHEMBL31013512 0.58 MEN1 (0.44) PGRGAAMEN1KMT2ANPC1
SCHEMBL28794504 0.58 PDK2 (0.53) HTR2CPGRCYP3A4MEN1KMT2A
SCHEMBL417566 0.58 CYP1A1 (0.54) TSHRMAP4K4CYP3A4TNKS2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759769-B2 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARMECEUTICAL INC (US) 2020-09-01 US disclosed
US-20190248754-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMECEUTICAL INC (US) 2019-08-15 US disclosed
US-10227312-B2 Glucosylceramide synthase inhibitors for the treatment of diseases BIOMARIN PHARMACEUTICAL INC. (US) 2019-03-12 US disclosed
US-20180044302-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2018-02-15 US disclosed
US-20180044302-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES BIOMARIN PHARMACEUTICAL INC. 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10759769-B2 Glucosylceramide synthase inhibitors for the treatment of diseases GBA1, UGCG, GBA2 UGCG 2/4885HTR2C 4562/4885PDE3B 566/4885
US-20180044302-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES GBA1, UGCG, GBA2 UGCG 2/4885HTR2C 4562/4885PDE3B 566/4885
US-20190248754-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES GBA1, UGCG, GBA2 UGCG 2/4885HTR2C 4562/4885PDE3B 566/4885
US-10227312-B2 Glucosylceramide synthase inhibitors for the treatment of diseases GBA1, UGCG, GBA2 UGCG 2/4885HTR2C 4562/4885PDE3B 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.